What does bringing AI into clinical practice look like? Explore real-world evaluations and hear from clinicians using EchoGo® in practice—from implementation experiences to perspectives on how its insights help inform further evaluation and patient management. Explore here: hubs.la/Q04BrjRt0 #HFpEF #CardiacAmyloidosis #ATTRCM #ClinicalAI

What context does the AFib live in? During our HRX Live roundtable, panelists explored the importance of looking beyond the arrhythmia to understand potential underlying conditions such as cardiac amyloidosis. That broader clinical picture matters when considering the next steps in a patient’s care. Watch the full roundtable on YouTube: hubs.la/Q04BkBw50 #AFib #CardiacAmyloidosis #Electrophysiology #HRX2026

🚨Now available on YouTube- Hidden in Plain Sight: Earlier Detection of HFpEF and Cardiac Amyloidosis to Improve AF Ablation and LAAC Outcomes Hear from Ultromics Chief Commercial Officer @rogerrowens and leading experts in electrophysiology as they discuss earlier recognition, implications for patient management, and what it takes to integrate AI into clinical workflows. Watch the full roundtable: hubs.la/Q04B4kJz0 #HRX2026 #AFib #HFpEF #CardiacAmyloidosis

Heading to #HFSA2026? Join us for two ePoster presentations exploring EchoGo®’s role in HFpEF and cardiac amyloidosis detection. Then stop by booth #811 to meet the team and learn more!

See you at #HFSA2026! Members of our commercial team will be on site and look forward to connecting. Stop by booth #811 to learn how EchoGo® supports detection of HFpEF and Cardiac Amyloidosis within routine echocardiography. #HFSA #HFpEF #ATTRCM #Amyloid #ClinicalAI

Earlier identification matters when it helps inform the path forward. Hear from Dr. Faizi Jamal at City of Hope and other clinicians about how they’re using EchoGo® in practice and what it means for their health systems: ultromics.com #CardiacAI #Echocardiography #HFpEF #CardiacAmyloidosis #ATTRCM

A recent @MPOmagazine article highlights independent findings from the American Heart Association AI Assessment Lab, which found EchoGo® Heart Failure could have identified HFpEF an average of 263 days earlier than standard care among patients who otherwise experienced delayed diagnosis. These findings help bridge the gap between AI’s potential and its practical value, providing clinicians and health systems with evidence to assess how EchoGo could support earlier consideration of HFpEF alongside physician judgment. Read the full article: mpo-mag.com/breaking-news/re… #AmericanHeartAssociation #HFpEF #Echocardiography #ClinicalAI

Today is World Heart Day ❤️ Cardiovascular disease accounts for nearly one in three deaths worldwide. Behind that number are people whose symptoms may be overlooked and whose heart conditions may go unrecognized. At Ultromics, we’re bringing AI insights into routine echocardiography to help clinicians flag conditions like HFpEF and cardiac amyloidosis sooner—and move patients toward appropriate care pathways earlier. Because every patient deserves the chance to get the care they need. #WorldHeartDay #HeartHealth #Cardiology

Last week at HRX, our roundtable explored how earlier identification of HFpEF and cardiac amyloidosis could inform care for patients undergoing AF ablation and LAAC—and how EchoGo® may support earlier consideration of these conditions through routine echocardiography. Thank you to everyone who shared their perspectives and made it such a thoughtful conversation. We’re also grateful to @experienceHRX for bringing us together for a great meeting! Panelists: Michael Raccuglia JR., @rogerrowens, Robert Kowal, @TinaBaykaner45, @NazemAkoum, @TJaredBunch

Ultromics CCO @rogerrowens and Northeast Regional Sales Director Kim Kenyon are at NYU Langone Health today for Advances in the Diagnosis and Treatment of Amyloidosis in 2026. We’re excited to join clinicians and researchers discussing advances in imaging, diagnosis, and treatment. Stop by our booth to learn how FDA-cleared EchoGo® Amyloidosis can support earlier consideration of cardiac amyloidosis—and what that could mean for your health system. #CardiacAmyloidosis #Echocardiography #CardiacAI

Ultromics is headed to Phoenix for #HFSA2026! We’re looking forward to supporting the meeting and connecting with attendees to share how Ultromics’ clinically validated AI can fit into existing workflows to support earlier detection of HFpEF and Cardiac Amyloidosis. #HFSA #HFpEF #ATTRCM #Amyloid #ClinicalAI

HFpEF and cardiac amyloidosis frequently hide behind a presentation of atrial fibrillation. If these conditions were identified earlier—before AF ablation or left atrial appendage closure—could those insights lead to more informed procedural decisions and better outcomes for patients? Join Ultromics CCO @rogerrowens and a panel of leading electrophysiology experts this Saturday at HRX as they explore this question and discuss the potential of earlier identification using Ultromics’ FDA-cleared EchoGo® platform. 🗓️ Saturday, September 19 | 10:45–11:30 a.m. EDT 🔗 hubs.la/Q04xNSdh0

See you at #ASNC2026! Members of our commercial team will be on site and look forward to connecting. Stop by booth #226 to learn how EchoGo® supports detection of HFpEF and Cardiac Amyloidosis within routine echocardiography.

Bringing AI into clinical practice requires evidence, integration, and a foundation built for real-world adoption. With FDA-cleared technology, peer-reviewed evidence, seamless workflow integration, and more than a decade of outcomes-linked data, Ultromics is helping healthcare organizations bring advanced AI into routine echocardiography to support HFpEF identification and cardiac amyloidosis screening. Learn more at hubs.la/Q04xbpzM0 #ClinicalAI #Echocardiography #HeartFailure #HFpEF #Amyloidosis

Patients presenting with atrial fibrillation may also be living with undetected HFpEF or cardiac amyloidosis. Could identifying these conditions earlier help inform decisions surrounding AF ablation and LAAC? Join Ultromics Chief Commercial Officer @rogerrowens and leading experts in electrophysiology at HRX Live for Hidden in Plain Sight: Earlier Detection of HFpEF and Cardiac Amyloidosis to Improve AF Ablation and LAAC Outcomes to learn more. September 19, 2026 10:45–11:30 a.m. EDT 🔗 hubs.la/Q04wZP260

Ultromics is headed to Las Vegas for #ASNC2026! We’re looking forward to supporting the meeting and connecting with attendees to share how Ultromics’ clinically validated AI is being applied within routine echocardiography to support detection of HFpEF and Cardiac Amyloidosis.

Cardiac amyloidosis remains widely underdiagnosed, leaving many patients without answers or access to appropriate care. EchoGo® Amyloidosis has been validated across diverse patient populations, demonstrating consistent performance in identifying signs of cardiac amyloidosis—even across challenging clinical subgroups. Using a single apical four-chamber view from a routine echocardiogram, it augments physician evaluation and may help connect patients to the appropriate care pathway sooner. #CardiacAmyloid #ATTRCM #Amyloid #Echocardiography

Cardiac amyloidosis remains underdiagnosed, with many patients experiencing significant delays before receiving a diagnosis. Among patients with HFpEF, studies have found an underlying prevalence of cardiac amyloidosis—highlighting an important opportunity for earlier clinical consideration. EchoGo® supports the detection of complex cardiac diseases, including HFpEF and cardiac amyloidosis. Learn more at hubs.la/Q04vCS3Y0 #HFpEF #ATTRCM #Amyloid #Echocardiography